Johnson & Johnson vs Royalty Pharma plc
JNJ vs RPRX — side-by-side comparison from reported financials. JNJ leads 6, RPRX leads 4 of 10 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Royalty Pharma plc
RPRX · Healthcare
$56.93+1.28%Solid
| Metric | JNJ | RPRX |
|---|---|---|
| Price | $261.79 | $56.93 |
| Market cap | $631B | $25.4B |
| Revenue (TTM) | $97.9B | $2.54B |
| Revenue growth | +5.6% | +2.1% |
| Net margin | 21.5% | 32.1% |
| Free cash flow | $22.2B | $2.98B |
| Net cash (debt) | ($27.8B) | ($7.93B) |
| 1-year price return | +37.0% | +57.5% |
| P/E | 29.9 | 40.2 |
| P/E vs own history (cheap-side %) | 16% | 53% |
| Dividend yield | 2.00% | 1.22% |
| Return on equity | 26% | 12% |
| Altman Z-score | — | 2.32 |
| CV checks passed | 10 of 11 | 10 of 11 |
| Employees | 140,800 | 100 |
Full résumé-style profiles: JNJ CV · RPRX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.